Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran ). part II. dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers

Oberyé, Janine; Mannaerts, Bernadette; Huisman, J.; Timmer, C. J.

doi:10.1016/s0015-0282(99)00414-8

Cited by 91 publications

(53 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in our study, the mean LH level in GnRH antagonist cycles was 9.88 IU/L, higher than the mean level from the pharmacodynamic study of ganirelix in female volunteers [34] and also in the COH cycles utilizing GnRH antagonist [6][7][8]. The possible explanation was the duration of administration of ganirelix in this study (averagely 3 days) which was shorter than the mentioned studies and it usually requires 2-3 days for ganirelix to reach the steady-state level [34].…”

Section: Discussioncontrasting

confidence: 88%

See 1 more Smart Citation

The effects of GnRH antagonist on the endometrium of normally menstruating women

Sirayapiwat

Suwajanakorn

Triratanachat

et al. 2007

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose To study the effects of GnRH antagonist (ganirelixOrgalutran®) on the endometrium of regularly menstruating women. Materials and methods Prospective, self-controlled study. The thirty-five volunteers were studied for two cycles: one as a control and the other, GnRH antagonist-treated cycles in which ganirelix 0.25 mg/d was given daily for 3 days, starting when the largest follicle reached 15 mm. In both cycles, serum estradiol, LH and endometrial thickness were measured when the largest follicle was ≥18 mm. Endometrial biopsy was performed on day 6 after ovulation for histological dating and morphometric study. Results No statistical differences between histological dating and the endometrial thickness in the control and GnRH antagonist-treated cycles. All morphometric parameters were also not different. Serum estradiol and LH levels were significantly lower in GnRH antagonist-treated cycles.Conclusion GnRH antagonist has no effect on the endometrium of regularly menstruating women as assessed by either histological dating or morphometric analysis.

show abstract

Section: Discussioncontrasting

confidence: 88%

“…Their mean (± SD) age was 31.7±2.8 years (ranged [26][27][28][29][30][31][32][33][34][35]. The mean (± SD) body mass index was 22.7±3.9 kg/m 2 (ranged 17.0-32.5).…”

Section: Resultsmentioning

confidence: 99%

The effects of GnRH antagonist on the endometrium of normally menstruating women

Sirayapiwat

Suwajanakorn

Triratanachat

et al. 2007

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…Ovarian stimulation for IVF is known to affect luteal phase function and, in natural cycle IVF, the endometrium has been found to show premature secretory changes in the postovulatory and early luteal phases of the cycle, followed by disproportionately high degrees of glandular and stromal differentiation in the mid-luteal phase. 25 In the protocol of the present study, although the doses of gonadotrophins (HMG and recombinant FSH) were significantly lower in the MNC procedure than in the COH procedure, a high level of oestradiol might be associated with premature expression of endometrial receptivity. Whether a lower dose of gonadotrophins is more effective in MNC and/or COH IVF is a subject for future research.…”

Section: Discussioncontrasting

confidence: 46%

Modified Natural Cycle for In Vitro Fertilization and Embryo Transfer in Normal Ovarion Responders

2010

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…Unfortunately LH and FSH could not be measured in the present study because these assays are problematic in the marmoset and there are restrictions in the volume of plasma that can be collected. However, a degree of residual level of gonadotrophin secretion would be expected to persist after GnRH antagonist treatment, with FSH being less suppressed than LH (Ditkoff et al 1991, Fluker et al 1991, Hall et al 1991, Nelson et al 1995, Oberye et al 1999. While this suppression is sufficient to reduce the ability of mature follicles to produce oestradiol, the low levels of LH and FSH remaining may be sufficient to maintain the activity of tertiary follicles.…”

Section: Discussionmentioning

confidence: 99%

Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary

Taylor¹,

Hillier²,

Fraser³

2004

Journal of Endocrinology

View full text Add to dashboard Cite

Angiogenesis is required for normal follicular development but the role of gonadotrophins in the control of follicular angiogenesis remains to be elucidated. This study investigated the effects of treatment with GnRH antagonist in vivo on follicular development and angiogenesis in the marmoset. GnRH antagonist was administered on either follicular day 0 or day 5 of the 10-day follicular phase with ovaries collected on day 10. Ovaries from control marmosets were studied at day 5 (mid follicular phase) and day 10 (periovulatory period). Ovaries were fixed, serial sectioned and subjected to morphological analysis and immunocytochemistry to determine cell proliferation and follicular endothelial cell area and in situ hybridization to assess changes in expression of vascular endothelial growth factor (VEGF). Treatment with GnRH antagonist from day 0-10 resulted in an absence of dominant preovulatory follicles seen in controls. In the remaining tertiary follicles granulosa, theca and endothelial cell proliferation was reduced, resulting in a minor reduction in vascular density. However, VEGF mRNA expression was unaffected by treatment. Treatment from day 5-10 did not prevent development of ovulatory size follicles, but they were atretic and lacked VEGF mRNA. These results suggest that while VEGF expression in the preovulatory follicle is under gonadotrophic control it is not dependent on normal gonadotrophin secretion in tertiary follicles, indicating that there are other paracrine factors regulating VEGF expression in the developing ovarian follicle.

show abstract

Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran ). part II. dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers

Cited by 91 publications

References 13 publications

The effects of GnRH antagonist on the endometrium of normally menstruating women

The effects of GnRH antagonist on the endometrium of normally menstruating women

Modified Natural Cycle for In Vitro Fertilization and Embryo Transfer in Normal Ovarion Responders

Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary

Contact Info

Product

Resources

About